Faster access than browser!
6 relations: Cannabinoid receptor antagonist, Cannabinoid receptor type 1, Obesity, Pfizer, Receptor antagonist, Rimonabant.
Cannabinoid receptor antagonist
A cannabinoid receptor antagonist, also known simply as a cannabinoid antagonist or as an anticannabinoid, is a type of cannabinoidergic drug that binds to cannabinoid receptors (CBR) and prevents their activation by endocannabinoids.
New!!: Otenabant and Cannabinoid receptor antagonist · See more »
Cannabinoid receptor type 1
The cannabinoid type 1 receptor, often abbreviated as CB1, is a G protein-coupled cannabinoid receptor located in the central and peripheral nervous system.
New!!: Otenabant and Cannabinoid receptor type 1 · See more »
Obesity
Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have a negative effect on health.
New!!: Otenabant and Obesity · See more »
Pfizer
Pfizer Inc. is an American pharmaceutical conglomerate headquartered in New York City, with its research headquarters in Groton, Connecticut.
New!!: Otenabant and Pfizer · See more »
Receptor antagonist
A receptor antagonist is a type of receptor ligand or drug that blocks or dampens a biological response by binding to and blocking a receptor rather than activating it like an agonist.
New!!: Otenabant and Receptor antagonist · See more »
Rimonabant
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States.
New!!: Otenabant and Rimonabant · See more »
Redirects here:
C25H25Cl2N7O, CP-945,598, Otenabant hydrochloride.
